Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS

NCT06189833 is registered in ClinicalTrials.gov with Stichting European Myeloma Network as lead sponsor.

NCT NCT06189833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06189833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS
Lead sponsor
Stichting European Myeloma Network
Phase
Phase 2
Overall status
Unknown status
Start date
November 23, 2023
Completion date
December 31, 2025
Enrollment
200 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma